ARTICLE | Clinical News
CG400549: Phase II start
May 7, 2012 7:00 AM UTC
This month, CrystalGenomics will begin an open-label, U.S. Phase II trial to evaluate once-daily CG400549 for 10-14 days in patients with cABSSSI due to methicillin-resistant Staphylococcus aureus (MR...